标题：基于网络药理学的蓝芩口服液治疗新型冠状病毒肺炎的分子机制研究

      作者：李研达 1，曾煜 2，刘旺 2    1.湛江市中心人民医院内科，广东 湛江 524000；2.广东医科大学附属第二医院呼吸与危重症医学科，广东 湛江 524000

      卷次： 2021年32卷7期

      【摘要】 目的 研究蓝芩口服液治疗新型冠状病毒肺炎的相关分子靶点及分子作用机制。方法 使用TCMSP数据库检索蓝芩口服液的主要活性成分及其作用靶点。使用GeneCards数据库，检索新型冠状病毒肺炎的疾病相关基因靶点。使用韦恩图对蓝芩口服液主要活性成分作用靶点及新型冠状病毒肺炎相关基因靶点取交集得到共同基因靶点。使用Cytoscape3.7.2软件构建药物-活性成分-作用靶点网络图。使用STRING数据库构建共同作用靶点的蛋白质相互作用PPI网络。使用DAVID数据对共同基因靶点进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。结果 筛选出蓝芩口服液主要活性成分91种，作用基因靶点205个，其中43个为蓝芩口服液与新型冠状病毒肺炎的共同基因靶点，靶点包括丝裂原活化蛋白激酶8 (MAPK8)、白介素6 (IL6)、白介素 10 (IL10)、CC型修饰趋化因子配体 2 (CCL2)等。GO和KEGG富集分析共得到 47个GO富集条目和 59个KEGG富集条目，涉及癌症通路、HIF-1信号通路、MAPK信号通路等。结论 蓝芩口服液在治疗COVID-19中有着多靶点调控、多方面作用的特点。
      【关键词】 新型冠状病毒肺炎；蓝芩口服液；网络药理学；富集分析；分子靶点；分子机制
      【中图分类号】 R511 【文献标识码】 A 【文章编号】 1003—6350（2021）07—0821—06

Molecular mechanism of Lanqin oral solution in the treatment of COVID-19 based on network pharmacology.
LIYan-da 1, ZENG Yu 2, LIU Wang 2. 1. Department of Internal Medicine, Zhanjiang Central People's Hospital, Zhanjiang524000, Guangdong, CHINA; 2. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital ofGuangdong Medical University, Zhanjiang 524000, Guangdong, CHINA
【Abstract】 Objective To investigate the molecular targets and molecular mechanism of Lanqin oral solution inthe treatment of coronavirus disease 2019 (COVID-19) based on network pharmacology. Methods Traditional ChineseMedicine Systems Pharmacology (TCMSP) database was used to screen out the main active components of Lanqin oralsolution and the targets of drug components. GeneCards database was used to screen out the gene targets which relatedto COVID-19. The common gene targets were obtained by the intersection of the main active components of Lanqin oralsolution and the COVID-19-related gene targets using the Veen diagram. STRING database was used to construct a pro-tein-protein interaction (PPI) network of common gene targets. Cytoscape 3.7.2 software was used to construct thedrug-active-component-target network. DAVID database was used to construct the GO enrichment analysis and KEGGenrichment analysis. Results Lanqin oral solution has 91 main active components, and 205 gene targets were identi-fied, of which 43 were the common gene targets of Lanqin oral solution and COVID-19, involving mitogen-activatedprotein kinase 8 (MAPK8), interleukin 6 (IL6), interleukin 10 (IL10), CC chemokine ligand 2 (CCL2), etc. The GO andKEGG enrichment analysis showed that there were 47 GO items and 59 KEGG items, involving pathways in cancer,HIF-1 signaling pathway and MAPK signaling pathway. Conclusion Lanqin oral solution has the characteristics ofmulti-target regulation and multi-function in the treatment of COVID-19.
      【Key words】 Coronavirus disease 2019 (COVID-19); Lanqin oral solution; Network pharmacology; Enrichmentanalysis; Molecular targets; Molecular mechanism